成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart 0 Sign in  

[ CAS No. 20724-73-6 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 20724-73-6
Chemical Structure| 20724-73-6
Structure of 20724-73-6 * Storage: {[proInfo.prStorage]}

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

Quality Control of [ 20724-73-6 ]

Related Doc. of [ 20724-73-6 ]

Alternatived Products of [ 20724-73-6 ]
Product Citations

Product Details of [ 20724-73-6 ]

CAS No. :20724-73-6 MDL No. :MFCD02682947
Formula : C10H15N3O5 Boiling Point : -
Linear Structure Formula :- InChI Key :PPUDLEUZKVJXSZ-VPCXQMTMSA-N
M.W : 257.24 Pubchem ID :500902
Synonyms :
2'-C-Methylcytidine;2CMC;mCyd ;2'-C-MeC
Chemical Name :4-Amino-1-((2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)pyrimidin-2(1H)-one

Safety of [ 20724-73-6 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 20724-73-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 20724-73-6 ]

[ 20724-73-6 ] Synthesis Path-Downstream   1~17

  • 1
  • [ 115494-62-7 ]
  • [ 20724-73-6 ]
YieldReaction ConditionsOperation in experiment
Even further illustrative of the present invention is a method for inhibiting RNA-dependent RNA viral polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection wherein the compound is selected from 2'-O-methyl-cytidine, 2'-C-methyl-cytidine, 3',5'-di-O-octanoyl-2'-O-methyl-cytidine, 3'-O-octanoyl-2'-O-methyl-cytidine, 4-amino-1-(beta-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine, 4-amino-7-(2-C-methyl-beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 4-amino-7-(2-C-methyl-beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxmide, 2'-C-methyladenosine, 8-amino-2'-C-methyladenosine, ...
Further illustrative of the invention is a method for inhibiting RNA-dependent RNA viral polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection wherein the compound is selected from: 2'-O-methyl-cytidine, 2'-C-methyl-cytidine, 3',5'-di-O-octanoyl-2'-O-methyl-cytidine, 3'-O-octanoyl-2'-O-methyl-cytidine, 4-amino-1-(beta-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine, 4-amino-7-(2-C-methyl-beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 4-amino-7-(2-C-methyl-beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide, 2'-C-methyladenosine, 8-amino-2'-C-methyladenosine, ...
Illustrative of the invention is a method for inhibiting RNA-dependent RNA viral polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection wherein the compound is selected from: 2'-O-methyl-cytidine, 2'-C-methyl-cytidine, 3',5'-di-O-octanoyl-2'-O-methyl-cytidine, 3'-O-octanoyl-2'-O-methyl-cytidine, 2'-C-methyl-adenosine, 8-amino-2'-C-methyladenosine, 4-amino-7-(2-C-methyl-beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 4-amino-7-(2-C-methyl-beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide, 3'-deoxy-3'-methyl-cytidine, ...
Yet further illustrative of the invention is a method for inhibiting RNA-dependent RNA viral polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection wherein the compound is selected from: 2'-O-methylcytidine, 2'-C-methylcytidine, 3',5'-di-O-octanoyl-2'-O-methyl-cytidine, 3'-O-octanoyl-2'-O-methyl-cytidine, 4-amino-7-(2-C-methyl-beta-D-ribofuranosyl)-7H-pyrrolo[2,3-dl]pyrimidine-5-carbontrile, 4-amino-7-(2-C-methyl-beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide, 2'-C-methyladenosine, 8-amino-2'-C-methyladenosine, 2'-O-methylcytidine-5'-[bis-(S-pivaloyl-2-thioethyl)phosphate], ...

  • 3
  • N4-benzoyl-2'-C-methyl-3',5'-di-O-benzoylcytidine [ No CAS ]
  • [ 20724-73-6 ]
  • 4
  • [ 4637-24-5 ]
  • [ 20724-73-6 ]
  • N4-[(dimethylamino)methylene]-2'-C-methyl-β-D-cytidine [ No CAS ]
  • 6
  • [ 13734-41-3 ]
  • [ 20724-73-6 ]
  • [ 640725-70-8 ]
YieldReaction ConditionsOperation in experiment
solution of N- (tert-butoxycarbonyl)-L-valine (46.50 g, 214 mmol.), CARBONYLDIIMIDAZOLE (34.70 G, 214 MMOL. ), AND ANHYDROUS TETRAHYDROFURAN (1000 ML) IN a 2 L round bottom flask, was stirred at 25 C under argon for 1.5 hours and then at 40- 50 C for 20 minutes. In a separate 5 L 5-necked round bottom flask, equipped with an overhead stirrer, cooling tower, temperature probe, addition funnel, and an argon line WAS ADDED 4-AMINO-L- (3, 4-DIHYDROXY-5-HYDROXYMETHYL-3-METHYL-TETRAHYDRO-FURAN-2-YL) - 1H-PYRIMIDINE-2-ONE (50.0 g, 195 MMOL.) and anhydrous N, N-DIMETHYLFORMAMIDE (1000 mL). This mixture was heated at 100 C for 20 minutes until all of the pyrimidine-2-one derivative compound went into solution, and then triethylamine (500 mL) and 4- dimethylaminopyridine (2.38 g, 19 mmol) were added to the solution. The mixture was next heated at 97 C for 20 minutes and the tetrahydrofuran solution was added slowly through an addition funnel over a period of 2 hours, maintaining the temperature no lower than 82 C. The reaction mixture was heated at 82 C for 1 hour and monitored by HPLC (product = 68%, SM = 11%, and impurity at about 12 min = 17%, excluding DIMETHYLAMINOPYRIDINE). The reaction mixture was cooled to room temperature and then triethylamine and tetrahydrofuran were removed under vacuum at 30 C. The solution was then neutralized with acetic acid to a pH of 7.69. N, N-DIMETHYLFORMAMIDINE was removed under vacuum at 35 C and chased with ethyl acetate (2 x 200 ML). The crude product was stirred with ethyl acetate (500 mL) and water (300 mL). The two layers were separated and the aqueous layer was extracted with ethyl acetate (500 mL). The combined organic layers were washed with an aqueous saturated brine solution (500 mL). Next the organic layer was extracted with an aqueous solution of malonic acid (4 x 400 mL, 10WT. %). The organic layer was checked by TLC (silica, 20% methanol in dichloromethane) to make sure that all the desired product was removed from the organic layer. The acidic aqueous extracts were combined and cooled in an ice bath and neutralized with triethylamine to a pH of 7.40 so that the solids fell out of solution.
  • 9
  • [ 20724-73-6 ]
  • <i>N</i>'-{1-[5-(<i>tert</i>-butyl-diphenyl-silanyloxymethyl)-3,4-dihydroxy-3-methyl-tetrahydro-furan-2-yl]-2-oxo-1,2-dihydro-pyrimidin-4-yl}-<i>N</i>,<i>N</i>-dimethyl-formamidine [ No CAS ]
  • 11
  • [ 20724-73-6 ]
  • 2-<i>tert</i>-butoxycarbonylamino-3-methyl-butyric acid 2-(<i>tert</i>-butyl-diphenyl-silanyloxymethyl)-5-[4-(dimethylamino-methyleneamino)-2-oxo-2<i>H</i>-pyrimidin-1-yl]-4-hydroxy-4-methyl-tetrahydro-furan-3-yl ester [ No CAS ]
  • 12
  • [ 23643-36-9 ]
  • [ 20724-73-6 ]
  • 13
  • (2S/R,3R,4R,5R)-5-((benzoyloxy)methyl)-3-methyltetrahydrofuran-2,3,4-triyltribenzoate [ No CAS ]
  • [ 20724-73-6 ]
  • 16
  • [ 116918-58-2 ]
  • [ 20724-73-6 ]
  • 17
  • [ 58-96-8 ]
  • [ 20724-73-6 ]
Recommend Products
Same Skeleton Products

Technical Information

Historical Records
; ;